and Nontuberculous Mycobacteria Coinfection of the Lungs.

Turk Thorac J 2017 Jan 1;18(1):23-26. Epub 2017 Jan 1.

Department of Pulmonary Diseases, Ataturk University School of Medicine, Erzurum, Turkey.

Tuberculosis is highly prevalent in our country and nontuberculous mycobacteria (NTM) are frequently found in respiratory specimens recently. A 65-year-old woman was admitted with complaints of fever, cough, weight loss, and hemoptysis. On the patient's chest radiography an upper lobe cavity in both lungs and consolidation was detected. Acid-fast bacilli 4+ were observed in smear of sputum and culture results and were observed together. The patient's treatment was arranged. Through this case, we want to emphasize that tuberculosis and nontuberculous mycobacterial disease can coexist.

Download full-text PDF

Source
http://dx.doi.org/10.5152/TurkThoracJ.2017.16034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783168PMC
January 2017
Get 20% Off Journals at LWW.com

Similar Publications

Preliminary, Real-world, Multicenter Experience With Omadacycline for Infections.

Open Forum Infect Dis 2021 Feb 7;8(2):ofab002. Epub 2021 Jan 7.

Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.

Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for . The majority of infections were of pulmonary origin (7/12; 58.3%). Read More

View Article and Full-Text PDF
February 2021

Bedaquiline as Treatment for Disseminated Nontuberculous Mycobacteria Infection in 2 Patients Co-Infected with HIV.

Emerg Infect Dis 2021 Mar;27(3):944-948

Nontuberculous mycobacteria can cause disseminated infections in immunocompromised patients and are challenging to treat because of antimicrobial resistance and adverse effects of prolonged multidrug treatment. We report successful treatment with bedaquiline, a novel antimycobacterial drug, as part of combination therapy for 2 patients with disseminated nontuberculous mycobacteria co-infected with HIV. Read More

View Article and Full-Text PDF

Severe Pulmonary Disease Caused by Mycolicibacter kumamotonensis.

Emerg Infect Dis 2021 Mar;27(3):962-964

Severe Mycolicibacter kumamotonensis-pulmonary disease was diagnosed in a 68-year-old immunocompetent woman in Greece; the disease was initially treated as tuberculosis. The patient responded favorably to a new treatment regimen of azithromycin, amikacin, moxifloxacin, and linezolid. Complete symptom resolution and radiologic improvement resulted. Read More

View Article and Full-Text PDF

Validity of Diagnosis Code-Based Claims to Identify Pulmonary NTM Disease in Bronchiectasis Patients.

Emerg Infect Dis 2021 Mar;27(3):982-985

Nontuberculous mycobacteria infection is increasing in incidence and can lead to chronic, debilitating pulmonary disease. We investigated the accuracy of diagnosis code-based nontuberculous mycobacteria lung disease claims among Medicare beneficiaries in the United States. We observed that these claims have moderate validity, but given their low sensitivity, incidence might be underestimated. Read More

View Article and Full-Text PDF

Extrapulmonary Nontuberculous Mycobacteria Infections in Hospitalized Patients, United States, 2009-2014.

Emerg Infect Dis 2021 Mar;27(3):845-852

Nontuberculous mycobacteria (NTM) cause pulmonary and extrapulmonary infections in susceptible persons. To characterize the epidemiology of skin and soft tissue (SST) and disseminated extrapulmonary infections caused by NTM in the United States, we used a large electronic health record database to examine clinical, demographic, and laboratory data for hospitalized patients with NTM isolated from extrapulmonary sources during 2009-2014. Using all unique inpatients as the denominator, we estimated prevalence and summarized cases by key characteristics. Read More

View Article and Full-Text PDF